BrightSpring Health Services (NASDAQ:BTSG) Reports Upbeat Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations

Healthcare services provider BrightSpring Health Services (NASDAQ:BTSG) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 23% year on year to $3.87 billion. The company’s full-year revenue guidance of $15.26 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.45 per share was 13% above analysts’ consensus estimates.

Is now the time to buy BrightSpring Health Services? Find out by accessing our full research report, it’s free.

"We are pleased with the Company’s second quarter results that reflect our quality focus, service level performance, and dedication to the patients we serve," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring.

Company Overview

Founded in 1974, BrightSpring Health Services (NASDAQ:BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, BrightSpring Health Services grew its sales at an impressive 20.2% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. BrightSpring Health Services’s annualized revenue growth of 23.9% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

We can dig further into the company’s revenue dynamics by analyzing its most important segment, Pharmacy. Over the last two years, BrightSpring Health Services’s Pharmacy revenue averaged 28.3% year-on-year growth.

This quarter, BrightSpring Health Services reported robust year-on-year revenue growth of 23%, and its $3.87 billion of revenue topped Wall Street estimates by 5.9%.

Looking ahead, sell-side analysts expect revenue to grow 12% over the next 12 months, a deceleration versus the last two years. We still think its growth trajectory is attractive given its scale and implies the market is baking in success for its products and services.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

BrightSpring Health Services’s adjusted operating margin has generally stayed the same over the last 12 months, averaging 3.8% over the last five years. This profitability was paltry for a healthcare business and caused by its suboptimal cost structure.

Analyzing the trend in its profitability, BrightSpring Health Services’s adjusted operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

In Q2, BrightSpring Health Services generated an adjusted operating margin profit margin of 3.9%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Cash Is King

If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.

BrightSpring Health Services has shown mediocre cash profitability relative to peers over the last five years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 1.3%, below what we’d expect for a healthcare business.

BrightSpring Health Services broke even from a free cash flow perspective in Q2. This cash profitability was in line with the comparable period last year and its five-year average.

Key Takeaways from BrightSpring Health Services’s Q2 Results

We were impressed by how significantly BrightSpring Health Services blew past analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 1.3% to $73.81 immediately following the results.

Indeed, BrightSpring Health Services had a rock-solid quarterly earnings result, but is this stock a good investment here? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).